02:16 AM EST, 11/04/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) logged 25.60 billion Danish kroner in adjusted net profit for the third quarter, compared with 29.18 billion kroner a year ago. Adjusted EPS moved to 5.79 kroner from 6.56 kroner year over year, a Wednesday filing showed. For the three months ended Sept. 30, adjusted net sales were 79.2 billion kroner versus 74.98 billion kroner previously, the Danish pharmaceutical company added. Analysts polled by FactSet were expecting 73.65 billion kroner in sales, 20.54 billion kroner in net income, and 4.80 kroner in EPS. For 2026, the company now expects adjusted sales and operating profit growth between -2% and +2% at constant exchange rates, compared with -6% to 0% projected earlier.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.